Financial Performance - The company's operating revenue for 2021 was approximately RMB 389.32 million, representing a year-on-year increase of 25.60% compared to RMB 309.98 million in 2020[24]. - The net profit attributable to shareholders of the listed company increased by 33.40% year-on-year to approximately RMB 95.59 million, up from RMB 71.66 million in 2020[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 42.20% year-on-year to approximately RMB 88.91 million[24]. - The total assets of the company increased by 43.18% year-on-year to approximately RMB 1.14 billion, up from RMB 795.96 million in 2020[25]. - The net assets attributable to shareholders of the listed company increased by 76.31% year-on-year to approximately RMB 803.13 million[25]. - The basic earnings per share for 2021 was RMB 1.32, a 6.45% increase from RMB 1.24 in 2020[26]. - The company's gross profit margin for the main business was 60.16%, which increased by 0.73 percentage points year-on-year[113]. - The revenue from the automation pharmacy segment was CNY 279,202,574.01, with a gross profit margin of 64.35%, showing a decrease of 1.25 percentage points[113]. - The company achieved a total R&D investment of ¥39,611,447.29 in the current year, representing a 22.86% increase compared to ¥32,242,358.85 in the previous year[83]. Cash Flow and Dividends - The company plans to distribute a cash dividend of 5 yuan (including tax) for every 10 shares, totaling 38.6 million yuan, which represents 40.38% of the net profit attributable to shareholders for 2021[5]. - The net cash flow from operating activities decreased by 66.09% year-on-year to approximately RMB 39.75 million, primarily due to an increase in advance payments for orders[27]. - The company’s cash flow must meet operational and developmental needs to implement cash dividends[194]. - The company will conduct profit distribution at least once a year, subject to meeting specific conditions such as profitability and positive retained earnings[194]. - The company has established a stable profit distribution policy, ensuring reasonable returns for investors while maintaining normal operations and long-term development[193]. Research and Development - The research and development expenditure accounted for 10.17% of operating revenue, slightly down from 10.40% in 2020[26]. - The company applied for 830 patents and obtained 372 patents by the end of 2021, enhancing its core competitiveness through innovation[39]. - The company has developed 8 core key technologies, with a total of 161 authorized invention patents, enhancing its capabilities in smart medical management[77]. - The company is currently testing an AI-based empty bottle recognition system for anesthesia drugs, which is in the trial production stage and aims to enhance safety in operating rooms[87]. - The company is focusing on expanding its market presence through innovative products and technologies, aiming for significant growth in the healthcare sector[85]. Market and Industry Outlook - The medical equipment industry is expected to accelerate growth starting in 2022, driven by the ongoing development of new medical infrastructure since 2020[41]. - The company is positioned to benefit from increasing hospital numbers and rising government healthcare spending, which are driving industry demand[150]. - The healthcare infrastructure development is expected to accelerate growth in the medical equipment industry starting from 2022, providing opportunities for the company[151]. - The company plans to expand its market presence by entering new regions and increasing its product offerings in 2022[164]. - Future guidance suggests a revenue growth target of 10-15% for the upcoming fiscal year[164]. Corporate Governance - The board consists of 9 directors, including 3 independent directors, ensuring compliance with governance regulations[155]. - The supervisory board has 3 members, including 1 employee representative, to ensure independent oversight of company operations[156]. - The company is committed to maintaining high corporate governance standards to protect shareholder interests[155]. - The company has not faced any penalties from securities regulatory authorities in the past three years[175]. - The company’s profit distribution principles align with regulatory requirements, ensuring protection of shareholder interests, particularly for minority investors[192]. Strategic Initiatives - The company aims to optimize its industrial structure and deepen its business development in the intelligent material management sector, targeting the smart medical project business segment[41]. - The company plans to enhance collaboration between upstream and downstream industries to improve operational efficiency and product development[151]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[164]. - The company plans to implement new marketing strategies aimed at increasing brand awareness and customer engagement, with a budget allocation of 50 million RMB[171]. - The company aims to improve operational efficiency, targeting a 15% reduction in costs through process optimization initiatives[171].

Financial Performance - The company's revenue for Q3 2021 reached ¥76,909,851.78, representing a year-over-year increase of 16.99%[5] - Net profit attributable to shareholders for Q3 2021 was ¥21,043,376.71, up 38.08% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥20,869,076.18, reflecting a 47.55% increase year-over-year[5] - Total revenue for the first three quarters of 2021 reached ¥207,372,660.68, representing a 32.8% increase compared to ¥156,120,858.32 in the same period of 2020[21] - The net profit for Q3 2021 was CNY 35,280,593.29, an increase of 43.6% compared to CNY 24,549,399.97 in Q3 2020[23] - The total revenue for the first nine months of 2021 reached CNY 239,276,476.51, up from CNY 194,255,176.28 in the same period of 2020, representing a growth of 23.2%[25] - The operating profit for Q3 2021 was CNY 42,368,052.81, compared to CNY 29,935,348.20 in Q3 2020, marking a year-over-year increase of 41.3%[23] - The company reported a total comprehensive income of CNY 36,072,788.89 for Q3 2021, compared to CNY 24,416,281.06 in Q3 2020, reflecting a growth of 47.5%[24] - Basic and diluted earnings per share for Q3 2021 were both CNY 0.56, an increase from CNY 0.49 in Q3 2020[24] - The total profit for Q3 2021 was CNY 42,355,915.12, an increase of 42.6% from CNY 29,673,453.19 in Q3 2020[23] Assets and Liabilities - Total assets as of the end of the reporting period amounted to ¥1,040,988,204.51, a 30.78% increase from the end of the previous year[6] - The total assets of the company as of September 30, 2021, amounted to ¥1,040,988,204.51, up from ¥795,961,547.06 at the end of 2020, marking a 30.8% increase[20] - The total liabilities decreased to ¥295,414,505.42 from ¥336,474,276.51, a reduction of 12.2%[20] - Total liabilities reached approximately $336.47 million, with current liabilities at $280.53 million and non-current liabilities at $55.94 million[31] - The company reported short-term borrowings of approximately $81.04 million and long-term borrowings of $50 million[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 4,188[13] - Zhang Yinhua holds 23,055,000 shares, representing 29.86% of total shares[13] - Xu Li holds 8,457,500 shares, representing 10.96% of total shares[13] - Wen Qingnan holds 4,745,000 shares, representing 6.15% of total shares[14] - Zhuhai Longmen Capital Management holds 3,865,000 shares, representing 5.01% of total shares[14] - Zhao Jianguang holds 2,750,000 shares, representing 3.56% of total shares[14] - Suzhou Desheng holds 2,500,000 shares, representing 3.24% of total shares[14] - The top ten shareholders collectively hold a significant portion of the company's shares, indicating concentrated ownership[15] - The company has not reported any significant changes in shareholder structure or new strategic initiatives in the current quarter[17] Research and Development - Research and development expenses for Q3 2021 totaled ¥10,928,441.66, which is 62.85% higher than the same period last year[6] - The proportion of R&D expenses to operating income increased to 14.21%, up 4 percentage points year-over-year[6] - Research and development expenses for the first three quarters of 2021 were ¥28,700,518.33, compared to ¥20,569,196.59 in 2020, indicating a 39.5% increase[22] Cash Flow - The net cash flow from operating activities decreased by 54.00% to ¥11,342,140.97, primarily due to increased payments related to ongoing orders[11] - The cash flow from operating activities for the first nine months of 2021 was CNY 11,342,140.97, down from CNY 24,658,538.25 in the same period of 2020[26] - The net cash flow from investing activities for the first nine months of 2021 was -CNY 220,457,336.50, compared to -CNY 44,116,285.00 in the same period of 2020, indicating increased investment outflows[27] - The net cash flow from financing activities for the first nine months of 2021 was CNY 204,908,649.91, significantly higher than CNY 39,426,217.02 in the same period of 2020[27] - The company’s cash and cash equivalents at the end of Q3 2021 stood at CNY 152,076,163.90, compared to CNY 80,933,686.41 at the end of Q3 2020[27] Audit and Compliance - There are no audit opinion types applicable for the quarterly financial statements[17] - The company adjusted its financial statements in accordance with the new leasing standards effective from January 1, 2021, impacting the recognition of right-of-use assets and lease liabilities[33] - The company reported a decrease in other comprehensive income of approximately -$792,195.60[32]

Financial Performance - The company's operating revenue for the first half of 2021 reached ¥130,462,808.90, representing a 44.35% increase compared to ¥90,382,443.30 in the same period last year[19]. - The net profit attributable to shareholders was ¥18,612,856.94, up 39.86% from ¥13,307,943.57 year-on-year[19]. - The net profit after deducting non-recurring gains and losses was ¥15,991,824.06, which is a significant increase of 120.08% compared to ¥7,266,407.39 in the previous year[19]. - Basic earnings per share for the first half of 2021 were ¥0.28, a 21.74% increase from ¥0.23 in the same period last year[20]. - Revenue increased by 44.35% compared to the same period last year, primarily due to an increase in orders[22]. - Net profit attributable to shareholders increased by 39.86% year-on-year, while net profit excluding non-recurring gains and losses surged by 120.08%, driven by revenue growth[22]. - The company reported a significant increase in net profit excluding non-recurring gains and losses, which reached ¥15.99 million, reflecting a growth of 120.08% year-on-year[88]. - The company achieved total revenue of ¥130,462,808.90, representing a year-on-year growth of 44.35%[97]. - The net profit attributable to the parent company reached ¥18,612,856.94, marking a 39.86% increase year-on-year[97]. - The company reported a significant increase in capital reserves to CNY 440,433,617.10 from CNY 185,357,124.57, representing a growth of approximately 137.5%[183]. Research and Development - The R&D investment as a percentage of operating revenue was 13.62%, down from 15.33% in the previous year[21]. - The total R&D investment for the current period is ¥17,772,076.67, representing a 28.24% increase compared to the previous period's ¥13,858,562.51[63]. - The company is currently developing a 5G-based unmanned pharmacy management platform with a total expected investment of ¥7,820,000, of which ¥694,000.59 has been invested this period[65]. - The company has obtained a total of 157 invention patents, 179 utility model patents, and 39 design patents cumulatively[62]. - The company has applied for 807 patents and has obtained 375 patents as of the reporting period, indicating a strong focus on innovation and technology development[87]. - Research and development expenses grew by 28.24% to ¥17,772,076.67, indicating a focus on innovation[99]. Product Development and Innovation - The company focuses on intelligent management of medical supplies, providing comprehensive solutions for medical institutions[26]. - The company aims to build a new smart healthcare system through its intelligent management devices and software platforms[26]. - The company has developed a series of automated pharmacy products, including PIVAS dispensing assistants and infusion sorting machines, aimed at improving medication safety and efficiency in hospitals[33]. - The company has launched innovative products such as infusion sorting machines and integrated intelligent dispensing libraries, leading industry demand[60]. - The company is actively developing new products to address the increasing demand for automated drug distribution in hospitals, including syringe sorting machines and infusion product sorting machines[87]. - The company is committed to continuous innovation and development of products suitable for the unique medical supply scenarios in China[60]. Market Expansion and Strategy - The company is actively expanding into new application areas beyond its current focus on hospitals and medical supply chains[26]. - Future strategies include continuous product upgrades and expansion into downstream application fields[26]. - The company is focusing on expanding its product line and application scenarios in response to opportunities in smart hospitals and new infrastructure[87]. - Market expansion plans include entering three new international markets by the end of 2021, which is expected to increase overall market share by 10%[126]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $100 million earmarked for potential targets[127]. - The company is exploring potential mergers and acquisitions to further expand its market reach and operational capabilities[166]. Risk Management - The company has outlined various risks and countermeasures in its report, emphasizing the importance of risk management in its operations[4]. - The company is facing risks related to core technology and personnel retention, which are critical for maintaining its competitive edge[90]. - The company faces risks related to supply chain disruptions, particularly in the OEM procurement model, which could impact business operations[92]. - There is a risk of weakened demand penetration among existing customers, necessitating continuous product development to meet evolving market needs[93]. - The company is addressing the impact of rising raw material prices through technological improvements and supply chain optimization[87]. Financial Position and Assets - The company's total assets increased by 29.06% to ¥1,027,249,607.65 from ¥795,961,547.06 at the end of the previous year[19]. - As of the end of the reporting period, cash and cash equivalents amounted to ¥217,955,231.34, representing 21.22% of total assets, a decrease from 21.67% in the previous year[101]. - The company reported a significant increase in prepayments, which rose by 49.06% to ¥39,870,919.80, attributed to an increase in orders[101]. - The company's short-term borrowings decreased by 68.09% to ¥25,861,077.29, primarily due to repayment of loans during the reporting period[102]. - The total value of restricted assets at the end of the reporting period was ¥173,433,113.95, primarily due to collateral for loans[104]. - The company’s inventory increased by 8.33% to ¥68,063,800.91, indicating a growth in stock levels[101]. Corporate Governance and Compliance - The company elected new board members, including Zhu Kai and Cui Lijie, while Yang Muwen and Kong Yongjun resigned[114]. - No profit distribution or capital reserve fund increase plans were proposed for the half-year period[116]. - The company reported no significant environmental penalties during the reporting period, adhering to national and local environmental protection standards[121]. - The company has implemented measures to avoid related party transactions, ensuring compliance with governance standards[142]. - The report indicates that there are no significant changes in the number of shares held by major shareholders or any new strategic investors during the reporting period[173].

Financial Performance - Operating revenue surged by 293.50% to CNY 39,949,459.16 compared to the same period last year[5] - Net profit attributable to shareholders reached CNY 5,894,796.45, a significant recovery from a loss of CNY 6,904,286.29 in the previous year[5] - The company reported an operating profit of ¥5,620,032.34 for Q1 2021, a turnaround from an operating loss of ¥7,824,375.82 in Q1 2020[23] - The net profit for Q1 2021 reached CNY 7,719,452.96, compared to a net loss of CNY 6,494,583.10 in the same period last year, marking a turnaround[26] - The total comprehensive income for Q1 2021 was CNY 7,357,956.13, compared to a loss of CNY 6,617,591.42 in Q1 2020[27] Assets and Liabilities - Total assets increased by 34.57% to CNY 1,071,133,160.03 compared to the end of the previous year[5] - The total assets as of March 31, 2021, amounted to ¥1,071,133,160.03, compared to ¥795,961,547.06 at the end of 2020, indicating growth in asset base[14] - The company's total liabilities decreased slightly to ¥304,168,422.96 in Q1 2021 from ¥307,168,877.94 in Q4 2020[20] - Total liabilities reached $307.17 million, including current liabilities of $251.65 million[40] Shareholder Information - Net assets attributable to shareholders rose by 61.45% to CNY 735,438,869.90 year-over-year[5] - The number of shareholders reached 9,986, with the top ten shareholders holding significant stakes[7] - Shareholders' equity increased to ¥723,302,239.06 in Q1 2021, up from ¥441,567,790.41 at the end of 2020, representing a growth of 63.8%[20] Cash Flow - Cash flow from operating activities improved to -CNY 5,974,945.98 from -CNY 15,516,824.03 year-over-year[5] - Cash inflows from operating activities amounted to CNY 97,643,895.27 in Q1 2021, up from CNY 50,246,007.12 in Q1 2020[29] - The total cash inflow from operating activities was ¥105,512,567.39 in Q1 2021, significantly higher than ¥41,591,343.97 in Q1 2020[32] Research and Development - R&D expenditure as a percentage of operating revenue decreased by 38.76 percentage points to 18.39%[5] - The company’s R&D expenses for Q1 2021 were ¥7,345,579.98, compared to ¥5,802,242.70 in Q1 2020, reflecting a year-over-year increase of 26.6%[23] - The company reported a decrease in credit impairment losses to CNY 54,227.03 in Q1 2021 from CNY 1,072,797.59 in Q1 2020[26] Financing Activities - The company received government subsidies amounting to CNY 292,612.68 during the reporting period[7] - Total cash inflow from financing activities reached ¥304,965,010.70 in Q1 2021, compared to ¥36,584,283.56 in Q1 2020, indicating a substantial increase in financing[32] - The cash flow from financing activities netted ¥273,806,687.66 in Q1 2021, compared to ¥28,300,202.20 in Q1 2020, reflecting a strong financing position[33] Investment and Capital Expenditure - Cash paid for purchasing fixed assets and other long-term assets was ¥18,102,852.60, up 119.07% from ¥8,263,685.57 in Q1 2020, reflecting increased investment in projects[11] - The company secured a project for an integrated intelligent storage and distribution system at the Kunshan Western Medical Center, with a bid amount of ¥48,866,500, exceeding 10% of the previous year's audited revenue[11] Financial Expenses - The company's financial expenses showed a significant decrease, reporting a gain of ¥816,884.31 compared to a loss of ¥344,518.93 in the previous year, attributed to increased exchange gains[10] - The company incurred financial expenses of CNY -880,665.91 in Q1 2021, a decrease from CNY 363,122.21 in Q1 2020[26] New Leasing Standards - The implementation of the new leasing standard began on January 1, 2021, affecting the recognition of right-of-use assets and lease liabilities[37] - The company implemented new leasing standards effective January 1, 2021, impacting asset and liability adjustments[42] - The cumulative impact of the new leasing standards adjusted the beginning retained earnings without affecting the profit and cash flow statements[42]

Financial Performance - The company's operating revenue for 2020 was approximately ¥309.98 million, representing a 6.37% increase compared to ¥291.43 million in 2019[19]. - Net profit attributable to shareholders increased by 33.80% to approximately ¥71.66 million in 2020 from ¥53.56 million in 2019[19]. - The basic earnings per share rose by 34.78% to ¥1.24 in 2020, compared to ¥0.92 in 2019[20]. - The net cash flow from operating activities surged by 115.92% to approximately ¥117.24 million in 2020, up from ¥54.30 million in 2019[19]. - The company's total assets increased by 33.06% to approximately ¥795.96 million at the end of 2020, compared to ¥598.21 million at the end of 2019[19]. - The company's net assets attributable to shareholders increased by 10.40% to approximately ¥455.53 million at the end of 2020, compared to ¥412.63 million at the end of 2019[19]. - The company achieved total revenue of ¥309,979,146.84, representing a year-on-year growth of 6.37%[94]. - Operating profit increased by 25.73% to ¥80,552,803.05, while net profit attributable to the parent company rose by 33.80% to ¥71,657,095.31[94]. Dividend Policy - The company plans to distribute a cash dividend of 3 RMB per 10 shares, totaling 23,160,000 RMB, which represents 32.32% of the net profit attributable to shareholders for 2020[5]. - The company does not plan to increase capital reserves or issue bonus shares[5]. - The company aims to distribute at least 10% of the distributable profit as cash dividends annually, with a cumulative distribution of at least 30% of the average annual distributable profit over the last three years[136]. - The cash dividend distribution policy will consider industry characteristics, development stage, operating model, profitability, and major capital expenditure plans[137]. - The company has committed to maintaining the total distribution amount unchanged even if there are changes in total share capital due to convertible bonds or other factors[138]. Research and Development - Research and development expenses accounted for 10.40% of operating revenue in 2020, up from 7.98% in 2019, indicating a strategic focus on innovation[20]. - The total R&D investment for the year was ¥32,242,358.85, representing a 38.68% increase compared to the previous year[65]. - The company is focusing on developing products related to "Internet+", 5G mobile pharmacy equipment, and personalized traditional Chinese medicine formulations, which has driven the increase in R&D expenses[66]. - The number of R&D personnel increased to 113, accounting for 20.81% of the total workforce, up from 19.81% in the previous period[74]. - The total compensation for R&D personnel rose to CNY 1,754.29 million, compared to CNY 1,214.78 million previously, marking an increase of 44.5%[74]. Market Position and Strategy - The company focuses on intelligent management of medical supplies, providing comprehensive solutions for various medical institutions, including automated pharmacies, wards, and logistics[31]. - The company is actively expanding its product lines and application areas, focusing on automation and intelligent solutions in the healthcare sector[31]. - The company has established long-term strategic partnerships with pharmaceutical supply chain service enterprises to enhance order acquisition through bidding and negotiations[49]. - The company is positioned in a rapidly growing industry with no authoritative market share data available, indicating potential for significant market expansion[55]. - The company is committed to meeting the diverse and customized needs of healthcare institutions through continuous product development and innovation[54]. Risk Management - The company has detailed various risks and countermeasures in its report, which can be found in the section discussing operational conditions[4]. - The company faces risks related to the loss of core technical and business personnel, which could impact product development and operational efficiency[85]. - The gross margin is subject to fluctuations due to changes in product sales prices, raw material costs, and market competition, which could adversely affect profitability if not managed effectively[86]. - The company acknowledges the risk of seasonal fluctuations in revenue, with a significant portion of income generated in the second half of the year due to customer procurement cycles[89]. - The company is committed to enhancing its internal management and risk control mechanisms to prevent operational risks and ensure sustainable development[83]. Corporate Governance - The company has established a comprehensive governance structure, including the formulation of various management systems to enhance corporate governance and ensure compliance with relevant laws and regulations[163]. - The company emphasizes timely and compliant information disclosure, ensuring that all investors are treated fairly and their right to information is protected[164]. - The company has implemented a voting mechanism for minority shareholders, allowing their votes to be counted separately on significant matters affecting their interests[164]. - The company has established a hotline for investor relations to facilitate communication and address inquiries from investors and media[164]. - The company has committed to full compliance with information disclosure obligations regarding share transfers[145]. Shareholder Information - The largest shareholder, Zhang Yinhua, holds 23,055,000 shares, representing 39.82% of the total shares[179]. - Xu Li is the second-largest shareholder with 8,457,500 shares, accounting for 14.61%[179]. - The company has no controlling shareholder or actual controller, as confirmed in the report[181]. - The total number of shares held by the chairman and general manager, Zhang Yinhua, remained unchanged at 23,055,000 shares, with a pre-tax compensation of 945,100 CNY[187]. - The total number of shares held by the company’s directors and senior management at the end of the reporting period was 31,977,500 shares, with a total pre-tax compensation amounting to 3,812,100 CNY[188]. Social Responsibility - The company donated self-service drug dispensing equipment to a hospital during the COVID-19 pandemic, demonstrating its commitment to social responsibility[169]. - The company maintains a focus on environmental protection, ensuring that its production processes comply with national standards and do not adversely affect the surrounding environment[171]. - The company has not experienced any significant administrative penalties related to environmental compliance during the reporting period[171]. Future Outlook - The company provided guidance for the next fiscal year, projecting revenue growth of B% and an expected total revenue of $C million[146]. - Overall, the company remains optimistic about future growth, driven by innovation and market expansion strategies[147]. - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the H sector[146]. - The management emphasized the importance of sustainability initiatives, aiming to reduce carbon emissions by I% over the next five years[147].